Survival Analysis and Prognostic Factors in Prostate Cancer Patients: A Single Center Experience in Eastern Anatolia

Yıl 2020, Cilt: 47 Sayı: 4, 796 - 805, 30.12.2020

Ali Yılmaz , Mehmet Bilici , Salim Başol Tekin

Öz

Objective: Prostate cancer (PC), one of the most common malignancies of the urogenital tract, is more common in older men and shows significant prognostic differences among individuals. In recent years, new grade groups and American Joint Committee on Cancer (AJCC) stage groups have been used to predict prognosis. However, there is limited information on the prognostic significance of this new system in PC patients in Turkey. In this study, we aimed to evaluate the follow-up results of patients with diagnosis of PC, and the clinical significance of the new prognostic staging system in this patient population in Eastern Anatolia Region.
Methods: Retrospectively, 141 PC patients being followed up in Erzurum Ataturk University of Medical Oncology Department were included in this study. The relationships between overall survival (OS) and progression free survival (PFS) and clinical-pathological parameters were analysed using Kaplan-Meier curves and compared with the log-rank test. Univariate and multivariate analysis were used to determine the prognostic significance of clinical and pathologic variables for PFS and OS.
Results: The median age of patients was 69 and the majority of them were stage IV patients (79.4%). The median value of prostate specific antigen (PSA) was 39 ng/mL and the median Gleason score was 8. The majority of the patients had PSA value of ≥ 20 ng / ml (61.7%) and Gleason grade group 5 (35.5%). The median PFS and OS values were 29 and 33 months, respectively. The 5-year survival rates were 50% for local-locoregional disease and 20% for metastatic disease. PFS and OS were longer in patients with good Eastern Cooperative Oncology Group (ECOG) performance status (0-1), early stage (I-II), undergone to surgery, having low PSA (< 10 ng / ml) and low Gleason group (1-2). According to the multivariate analysis; stage, PSA and Gleason grade group were independent prognostic factors for both PFS and OS.
Conclusion: The new grading system, PSA and AJCC staging system are independent prognostic factors in patients with PC. Considering that patients in our region have shorter life spans compared to the world, these prognostic factors should be used more effectively in daily practice in determination of treatment strategy.

Anahtar Kelimeler

Gleason grade group, Prostate cancer, PSA

Kaynakça

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
• 2. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1): 7-34. PMID: 30620402. DOI:10.3322/caac.21551.
• 3. Ito K, Oki R, Sekine Y, et al. Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening. Int J Urol. 2019;26(10):956-970. PMID: 31183923.DOI: 10.1111/iju.14039.
• 4. globocan.iarc.fr. Last accessed on 27/11/2019
• 5. Parker C, Gillessen S, Heidenreich A, Horwich A. Annals of Oncology. 2015;26 (Supplement 5): v69–v77.doi:10.1093/annonc/mdv222
• 6. Damber JE. Endocrine therapy for prostate cancer. Acta Oncol. 2005;44(6):605–609.
• 7. Katzenwadel A, Wolf P. Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett. 2015;367(1):12–17.
• 8. Tucci M, Scagliotti GV, Vignani F. Metastatic castration resistant prostate cancer: time for innovation. Future Oncol (Lond,Engl). 2015;11(1):91–106.
• 9. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
• 10. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy- naive men with metastatic castration-resistant prostate cancer (COUAA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160.
• 11. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (Lond Engl). 2010;376(9747):1147–1154.
• 12. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.
• 13. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
• 14. Shariat SF, Kattan MW, Vickers AJ, et al. Critical review of prostate cancer predictive tools. Future Oncol. 2009; 5:1555-84.
• 15. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 20(19): 3972-3982, 2002. PMID: 12351594. DOI: 10.1200/JCO.2002.11.021.
• 16. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormonerefractory metastatic prostate cancer. J Clin Oncol. 2003;21(7): 1232-1237. PMID: 12663709. DOI: 10.1200/JCO.2003.06.100.
• 17. Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer – Major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67: 245–53.
• 18. Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. Switzerland: Springer; 2017.
• 19. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016; 40: 244–52.
• 20. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019.
• 21. Shao Y-H, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009; 101:1280–3.
• 22. Takemura K, Ito M, Nakanıshı Y, et al. Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide. Antıcancer Research. 2019;39:5773-5780.
• 23. Man Y, Chen Y. Systemic immune‑inflammation index, serum albumin, and fibrinogen impact prognosis in castration‑resistant prostate cancer patients treated with first‑line docetaxel. International Urology and Nephrology 2019. https://doi.org/10.1007/s11255-019-02265-4.
• 24. Lolli C, Caffo O, Scarpi E, et al. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Frontiers in Pharmacology. 2016;13;7:376.
• 25. Chen C, Chen Y, Hu LK, et al. The performance of the new prognostic grade and stage groups in conservatively treated prostate cancer. Asian Journal of Andrology. 2018;20, 366–371.
• 26. Spratt DE, Jackson WC, Abugharib A, et al. Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis. 2016;19(3):292-7.
• 27. Leapman MS, Cowan JE, Simko J, et al. Application of a prognostic Gleason grade grouping system to assess distant prostate cancer outcomes. Eur Urol 2017; 71: 750–9.
• 28. Abdel-Rahman O. Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV? PLoS One. 2017;28:12(11):e0188450.
• 29. Lauren C, Harshman LC, Chen YH, et al. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018;1:36(4):376-382.
• 30. Laurence C, Reijkeb TM, Schroder FH. Prostate Specific Antigen: APrognostic Marker of Survival in Good Prognosis Metastatic ProstateCancer? (EORTC 30892). European Urology. 2003; 44:182–189.